BRPI1008441A2 - anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira. - Google Patents

anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.

Info

Publication number: BRPI1008441A2
Authority: BR; Brazil
Prior art keywords: antibody; humanized; composition; treating; subject
Prior art date: 2009-02-16

Application number

BRPI1008441A

Other languages

English (en)

Inventor

David G Williams

Original Assignee

Biolex Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-02-16

Filing date

2010-02-16

Publication date

2016-10-11

2010-02-16 Application filed by Biolex Therapeutics Inc filed Critical Biolex Therapeutics Inc

2016-10-11 Publication of BRPI1008441A2 publication Critical patent/BRPI1008441A2/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/13—Immunoglobulins specific features characterized by their source of isolation or production isolated from plants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI1008441A 2009-02-16 2010-02-16 anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira. BRPI1008441A2 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US15277809P	2009-02-16	2009-02-16
US15349909P	2009-02-18	2009-02-18
PCT/US2010/000449 WO2010093480A2 (en)	2009-02-16	2010-02-16	Humanized anti-cd20 antibodies and methods of use

Publications (1)

Publication Number	Publication Date
BRPI1008441A2 true BRPI1008441A2 (pt)	2016-10-11

Family

ID=42562242

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI1008441A BRPI1008441A2 (pt)	2009-02-16	2010-02-16	anticorpo humanizado, composição farmacêutica, método para tratar e prevenir um distúrbio de célula b em sujeito, composição de anticorpo anti-cd-20 humanizado, ácido nucléico isolado e célula hospedeira.

Country Status (12)

Country	Link
US (1)	US20100303808A1 (pt)
EP (1)	EP2396416A4 (pt)
JP (1)	JP2012517806A (pt)
KR (1)	KR20110128876A (pt)
CN (1)	CN102439163A (pt)
AU (1)	AU2010214082A1 (pt)
BR (1)	BRPI1008441A2 (pt)
CA (1)	CA2752286A1 (pt)
IL (1)	IL214627A0 (pt)
MX (1)	MX2011008611A (pt)
WO (1)	WO2010093480A2 (pt)
ZA (1)	ZA201106697B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7601689B2 (en) *	2007-04-12	2009-10-13	Naidu Lp	Angiogenin complexes (ANGex) and uses thereof
AU2012236511B2 (en) *	2011-03-30	2016-04-28	Arizona Board Of Regents, For And On Behalf Of, Arizona State University	Auristatin tyramine phosphate salts and auristatin aminoquinoline derivatives and prodrugs thereof
BR112013033944A2 (pt) *	2011-07-06	2017-12-19	Morphosys Ag	combinação sinérgica
ES2684173T3 (es) *	2011-09-01	2018-10-01	Eisai R&D Management Co., Ltd.	Anticuerpos anti-XCR1 humano
CN107384932B (zh) *	2016-08-31	2020-10-20	北京天广实生物技术股份有限公司	抗人cd20人源化单克隆抗体mil62、其制备方法及用途
CN110352068A (zh)	2016-12-02	2019-10-18	南加利福尼亚大学	合成的免疫受体及其使用方法
CA3045944A1 (en)	2016-12-07	2018-06-14	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
CA3054632A1 (en)	2017-03-30	2018-10-04	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
US12227565B2 (en)	2018-06-20	2025-02-18	Biora Therapeutics, Inc.	Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
CN113348011B (zh)	2018-11-19	2023-04-18	比奥拉治疗股份有限公司	用生物治疗剂治疗疾病的方法和装置
JP7723420B2 (ja) *	2019-08-28	2025-08-14	キングス・カレッジ・ロンドン	Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤
CN114555117A (zh) *	2019-10-12	2022-05-27	百奥泰生物制药股份有限公司	抗cd20抗体制剂及抗cd20抗体在治疗cd20阳性疾病中的应用
CN121197633A (zh)	2019-12-13	2025-12-26	比特比德科有限责任公司	用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7321026B2 (en) *	2001-06-27	2008-01-22	Skytech Technology Limited	Framework-patched immunoglobulins
CA2476166C (en) *	2002-02-14	2011-11-15	Immunomedics, Inc.	Anti-cd20 antibodies and fusion proteins thereof and methods of use
HUE035898T2 (en) *	2002-12-16	2018-05-28	Genentech Inc	Immunoglobulin variants and their applications
CN1748143A (zh) *	2002-12-16	2006-03-15	健泰科生物技术公司	表达人cd20和/或cd16的转基因小鼠
KR101351122B1 (ko) *	2003-05-09	2014-01-14	듀크 유니버시티	Ｃｄ２０-특이적 항체 및 이를 이용한 방법
CN101151278A (zh) *	2005-02-07	2008-03-26	健泰科生物技术公司	Cd20抗体变体及其用途
ES2359854T3 (es) *	2005-03-31	2011-05-27	Biomedics Inc.	Anticuerpo monoclonal anti-cd20.
US9382327B2 (en) *	2006-10-10	2016-07-05	Vaccinex, Inc.	Anti-CD20 antibodies and methods of use
CN100455598C (zh) *	2006-11-29	2009-01-28	中国抗体制药有限公司	功能人源化抗人cd20抗体及其应用

2010
- 2010-02-16 MX MX2011008611A patent/MX2011008611A/es not_active Application Discontinuation
- 2010-02-16 CA CA2752286A patent/CA2752286A1/en not_active Abandoned
- 2010-02-16 KR KR1020117021712A patent/KR20110128876A/ko not_active Withdrawn
- 2010-02-16 BR BRPI1008441A patent/BRPI1008441A2/pt not_active IP Right Cessation
- 2010-02-16 EP EP10741539A patent/EP2396416A4/en not_active Withdrawn
- 2010-02-16 AU AU2010214082A patent/AU2010214082A1/en not_active Abandoned
- 2010-02-16 JP JP2011550135A patent/JP2012517806A/ja active Pending
- 2010-02-16 WO PCT/US2010/000449 patent/WO2010093480A2/en not_active Ceased
- 2010-02-16 CN CN2010800164497A patent/CN102439163A/zh active Pending
- 2010-03-09 US US12/720,483 patent/US20100303808A1/en not_active Abandoned
2011
- 2011-08-11 IL IL214627A patent/IL214627A0/en unknown
- 2011-09-13 ZA ZA2011/06697A patent/ZA201106697B/en unknown

Also Published As

Publication number	Publication date
EP2396416A4 (en)	2013-02-27
KR20110128876A (ko)	2011-11-30
CA2752286A1 (en)	2010-08-19
AU2010214082A1 (en)	2011-10-13
US20100303808A1 (en)	2010-12-02
CN102439163A (zh)	2012-05-02
EP2396416A1 (en)	2011-12-21
WO2010093480A2 (en)	2010-08-19
IL214627A0 (en)	2011-09-27
JP2012517806A (ja)	2012-08-09
MX2011008611A (es)	2011-10-21
ZA201106697B (en)	2014-01-29

Similar Documents

Publication	Publication Date	Title
BRPI1011324A2 (pt)	2016-03-15	sistema, método e cliente para participação em grupo
BR112014027166A2 (pt)	2017-06-27	anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
BR112014002621A2 (pt)	2017-12-12	anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BR112012024287A2 (pt)	2017-03-01	anticorpo, composição farmacêutica, método, ácido nucleico, vetor de expressão e célula hospedeira
BR112014013246A8 (pt)	2017-06-13	composição catalisadora, e, método para tratar nox
BR112012022046A2 (pt)	2017-02-14	''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
BR112012003809A2 (pt)	2019-09-24	anticorpa monoclonal isolado ou porção de ligação a antígeno do mesmo, composição e, método para tratar câncer em um indivíduo.
BR112012018947A8 (pt)	2017-12-19	composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BR112012018951A2 (pt)	2017-06-27	composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BR112014003598A2 (pt)	2017-12-12	molécula de ligação de antígeno biespecífica, polinucleotídeo isolado, vetor de expressão, célula hospedeira, método para produzir a molécula de ligação de antígeno biespecífica, composição farmacêutica, uso e método para tratar uma doença em um indivíduo
BR112014001258A2 (pt)	2017-02-21	método de tipagem de dna, e, conjuntos de iniciadores para tipagem de dna
CL2014000449A1 (es)	2015-01-16	Anticuerpo monoclonal anti iap humano, antagonista de la union de iap con shps-1; metodo de inhibicion de igf-1; y sus usos terapeuticos.
BR112013030520A2 (pt)	2017-03-21	método, sistema, e, composição.
BR112012010299A2 (pt)	2016-03-29	método implementado por computador, e, sistema para a realização de um método de caracterização
EP2660706A4 (en)	2015-01-21	METHOD AND SYSTEM FOR MANAGING AND CONTROLLING DOCUMENT PRINTING AND DOCUMENT SOURCE SCREENING
BRPI0910573A2 (pt)	2015-09-29	sistema para processar um pagamento de seguro de propriedade, e, método e sistema para prever pagamento de seguro de propriedade
BRPI0823030A2 (pt)	2015-07-28	Sistema de elevador, e, método para fazer um sistema de elevador.
BRPI0816094A2 (pt)	2015-03-03	Anticorpo, polipeptídeo, hibridoma, composição farmacêutica, método para inibir o desenvolvimento de tumor em um mamífero, polinucleotídeo, célula hospedeira, e, método para produzir um anticorpo.
BR112013031907A2 (pt)	2016-12-13	sistema, método e programa de computador para prever geomatria de poço
BRPI0810211A2 (pt)	2014-10-21	Citolisina dependente de colesterol mutante purficada, composição, vacina, método para vacinar um paciente, anticorpo monoclonal, ácido nucléico, e, célula hospedeira.
BR112013033277A2 (pt)	2017-03-01	catalisador de óxido, e, método para produzir o mesmo
BR112013015930A2 (pt)	2017-03-21	método para analisar pelo menos um fragmento emergindo de um poço, e conjunto para analisar pelo menos um fragmento emergindo de um poço.
BRPI1011623A2 (pt)	2016-03-22	método de alimentação para feixes cultivados, e, sistema de alimentação.
BRPI0919377A2 (pt)	2016-09-27	anticorpo isolado ou um fragmento ligante de antígeno do memso, ácido nucleico isolado, vetor, célula hospedeira, composição farmacêutica, método de produzir o referido anticorpo ou fragmento, uso dos mesmos, e composição compreendendo o referido anticorpo ou fragmento
EP2732460A4 (en)	2015-05-27	HARDENABLE COMPOSITION FOR PRESENTATIONS, MODELING PROCEDURES AND PATTERNS

Legal Events

Date	Code	Title	Description
2017-01-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE AS 6A E 7A ANUIDADES.
2017-05-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
2017-06-06	B25B	Requested transfer of rights rejected	Owner name: BIOLEX THERAPEUTICS, INC. (US)
2021-06-08	B350	Update of information on the portal [chapter 15.35 patent gazette]